{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:47:25Z","timestamp":1764510445725},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,10,30]],"date-time":"2012-10-30T00:00:00Z","timestamp":1351555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s12185-012-1202-y","type":"journal-article","created":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T21:21:03Z","timestamp":1351545663000},"page":"544-551","source":"Crossref","is-referenced-by-count":21,"title":["Current and future management of follicular lymphoma"],"prefix":"10.1007","volume":"96","author":[{"given":"Gilles","family":"Salles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,30]]},"reference":[{"key":"1202_CR1","doi-asserted-by":"crossref","unstructured":"Pulte D, Gondos A, Brenner H, editors. Expected long-term survival of older patients diagnosed with non-Hodgkin lymphoma in 2008\u20132012. Netherlands; 2012.","DOI":"10.1016\/j.canep.2011.08.006"},{"issue":"5","key":"1202_CR2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258\u201365.","journal-title":"Blood"},{"key":"1202_CR3","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","volume":"27","author":"JW Friedberg","year":"2009","unstructured":"Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27:1202\u20138.","journal-title":"J Clin Oncol"},{"key":"1202_CR4","doi-asserted-by":"crossref","unstructured":"Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi59\u201363.","DOI":"10.1093\/annonc\/mdr388"},{"issue":"3","key":"1202_CR5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.6004\/jnccn.2010.0021","volume":"8","author":"AD Zelenetz","year":"2010","unstructured":"Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin\u2019s lymphomas. J Natl Compr Cancer Netw. 2010;8(3):288\u2013334.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1202_CR6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","volume":"100","author":"L Lowry","year":"2011","unstructured":"Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100:86\u201392.","journal-title":"Radiother Oncol"},{"issue":"16","key":"1202_CR7","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.25149","volume":"116","author":"TJ Pugh","year":"2010","unstructured":"Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis. Cancer. 2010;116(16):3843\u201351.","journal-title":"Cancer"},{"issue":"8","key":"1202_CR8","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","volume":"22","author":"R Advani","year":"2004","unstructured":"Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin\u2019s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22(8):1454\u20139.","journal-title":"J Clin Oncol"},{"issue":"27","key":"1202_CR9","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","volume":"30","author":"JW Friedberg","year":"2012","unstructured":"Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J, Cerhan JR, Zelenetz AD, Hirata J, Miller TP. Effectiveness of first-line management strategies for stage i follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol. 2012;30(27):3368\u201375.","journal-title":"J Clin Oncol"},{"issue":"2 Suppl 2","key":"1202_CR10","first-page":"11","volume":"25","author":"RC Young","year":"1988","unstructured":"Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT Jr. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988;25(2 Suppl 2):11\u20136.","journal-title":"Semin Hematol"},{"issue":"3","key":"1202_CR11","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 1997;15(3):1110\u20137.","journal-title":"J Clin Oncol"},{"key":"1202_CR12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362:516\u201322.","journal-title":"Lancet"},{"issue":"10","key":"1202_CR13","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V95.10.3052","volume":"95","author":"JD Hainsworth","year":"2000","unstructured":"Hainsworth JD, Burris HA 3rd, Morrissey LH, Litchy S, Scullin DC Jr, Bearden JD III, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000;95(10):3052\u20136.","journal-title":"Blood"},{"issue":"1","key":"1202_CR14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","volume":"97","author":"P Colombat","year":"2001","unstructured":"Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97(1):101\u20136.","journal-title":"Blood"},{"issue":"4","key":"1202_CR15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","volume":"23","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005;23(4):705\u201311.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1202_CR16","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/annonc\/mds177","volume":"23","author":"P Colombat","year":"2012","unstructured":"Colombat P, Brousse N, Salles G, Morschhauser F, Brice P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Tilly H, Thieblemont C, Bergougnoux L, Lazreg F, Solal-Celigny P. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Ann Oncol. 2012;23(9):2380\u20135.","journal-title":"Ann Oncol"},{"key":"1202_CR17","doi-asserted-by":"crossref","unstructured":"Ardeshna KM, Qian W, Smith P, Warden J, Stevens L, Pocock CFE, et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (Grades 1, 2 and 3a). a preliminary analysis. ASH annual meeting 2010, Abstracts;116(21):6.","DOI":"10.1182\/blood.V116.21.6.6"},{"key":"1202_CR18","doi-asserted-by":"crossref","unstructured":"Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, et al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. ASH Annual Meeting 2011, Abstracts;118(21):LBA-6.","DOI":"10.1182\/blood.V118.21.LBA-6.LBA-6"},{"issue":"Suppl 4","key":"1202_CR19","first-page":"iv88","volume":"22","author":"KM Ardeshna","year":"2011","unstructured":"Ardeshna KM, Qian W, Stephens R, Smith P, Warden J, Lowry L, et al. Preliminary results of quality of life (Qol) analyses from the intergroup phase Iii randomised trial of rituximab vs a watch and wait approach in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma (FL). Ann Oncol. 2011;22(Suppl 4):iv88.","journal-title":"Ann Oncol"},{"issue":"28","key":"1202_CR20","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, et al. Phase III study of R\u2013CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579\u201386.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1202_CR21","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25(15):1986\u201392.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1202_CR22","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma Study Group. Blood. 2005;106(12):3725\u201332.","journal-title":"Blood"},{"key":"1202_CR23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42\u201351.","journal-title":"Lancet"},{"issue":"4","key":"1202_CR24","first-page":"CD003805","volume":"17","author":"H Schulz","year":"2007","unstructured":"Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A. Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin\u2019s lymphoma. Cochrane Database Syst Rev. 2007;17(4):CD003805.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 4","key":"1202_CR25","first-page":"iv88","volume":"22","author":"F Morschhauser","year":"2011","unstructured":"Morschhauser F, Seymour JF, Feugier P, Offner F, Lopez-Guillermo A, Bouabdallah R, et al. Impact of induction chemotherapy regimen on response, safety and outcome in the Prima Study. Ann Oncol. 2011;22(suppl 4):iv88.","journal-title":"Ann Oncol"},{"key":"1202_CR26","doi-asserted-by":"crossref","unstructured":"Federico M, et al. R\u2013CVP versus R\u2013CHOP versus R\u2013FM as first-line therapy for advanced-stage follicular lymphoma: final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL). ASCO meeting abstracts, May 2012; 30:8006.","DOI":"10.1200\/jco.2012.30.15_suppl.8006"},{"key":"1202_CR27","doi-asserted-by":"crossref","unstructured":"Nastoupil L, Sinha R, Byrtek M, Taylor M, Cerhan JR, Friedberg J, et al. A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (FL) used in the United States. ASH annual meeting 2011, Abstracts;118(21):97.","DOI":"10.1182\/blood.V118.21.97.97"},{"key":"1202_CR28","first-page":"3","volume":"30","author":"MJ Rummel","year":"2012","unstructured":"Rummel MJ, et al. Bendamustine plus rituximab (B\u2013R) versus CHOP plus rituximab (CHOP\u2013R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. ASCO Meeting Abstr. 2012;30:3.","journal-title":"ASCO Meeting Abstr"},{"issue":"32","key":"1202_CR29","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","volume":"26","author":"F Morschhauser","year":"2008","unstructured":"Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26(32):5156\u201364.","journal-title":"J Clin Oncol"},{"key":"1202_CR30","unstructured":"Hagenbeek A, Radford J, Van Hoof A, Vitolo U, Rohatiner AZS, Salles G, et al. 90Y-Ibritumomab tiuxetan (Zevalin(R)) consolidation of first remission in advanced-stage follicular non-Hodgkin\u2019s lymphoma: updated results after a median follow-up of 66.2 months from the international, randomized, phase III first-line indolent trial (FIT) in 414 patients. ASH annual meeting abstracts 2010;116(21):594."},{"key":"1202_CR31","unstructured":"Press OW, Unger JM, Rimsza LM, Friedberg J, LeBlanc M, Czuczman MS, et al. A phase III randomized intergroup trial (SWOG S0016) of CHOP chemotherapy plus rituximab vs. CHOP chemotherapy plus iodine-131-tositumomab for the treatment of newly diagnosed follicular non-Hodgkin\u2019s lymphoma. ASH Annual Meeting Abstracts 2011;118(21):98."},{"issue":"13","key":"1202_CR32","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1182\/blood-2012-05-431825","volume":"120","author":"H Ghesqui\u00e8res","year":"2012","unstructured":"Ghesqui\u00e8res H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, Soubeyran P, Perrot A, Brice P, Bouabdallah R, Sonet A, Dupuis J, Casasnovas O, Catalano JV, Delmer A, Jardin F, Verney A, Dartigues P, Salles G. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood. 2012;120(13):2650\u20137.","journal-title":"Blood"},{"key":"1202_CR33","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/jnci\/djr418","volume":"103","author":"L Vidal","year":"2011","unstructured":"Vidal L, Gafter-Gvili A, Salles G, Dreyling MH, Ghielmini M, Hsu Schmitz SF, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2011;103:1799\u2013806.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"1202_CR34","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH Oers van","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295\u2013301.","journal-title":"Blood"},{"issue":"13","key":"1202_CR35","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R\u2013FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108(13):4003\u20138.","journal-title":"Blood"},{"key":"1202_CR36","doi-asserted-by":"crossref","unstructured":"Pettengell R, Schmitz N, Gisselbrecht C, et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. J Clin Oncol. 2010;28(15 s):suppl;abstr 8005.","DOI":"10.1200\/jco.2010.28.15_suppl.8005"},{"issue":"21","key":"1202_CR37","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21(21):3918\u201327.","journal-title":"J Clin Oncol"},{"key":"1202_CR38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.beha.2011.03.001","volume":"24","author":"E Bachy","year":"2011","unstructured":"Bachy E, Salles G. Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL. Best Pract Res Clin Haematol. 2011;24:257\u201370.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"21","key":"1202_CR39","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","volume":"26","author":"C Sebban","year":"2008","unstructured":"Sebban C, Brice P, Delarue R, et al. Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol. 2008;26(21):3614\u201320.","journal-title":"J Clin Oncol"},{"key":"1202_CR40","doi-asserted-by":"crossref","unstructured":"Le Gouill S, De Guibert S, Planche L, et al., eds. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study; 2011. Haematologica; No. 96.","DOI":"10.3324\/haematol.2010.030320"},{"issue":"21","key":"1202_CR41","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159\u201369.","journal-title":"N Engl J Med"},{"key":"1202_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-385991-4.00001-5","volume":"111","author":"S Roulland","year":"2011","unstructured":"Roulland S, Faroudi M, Mamessier E, Sungalee S, Salles G, Nadel B. Early steps of follicular lymphoma pathogenesis. Adv Immunol. 2011;111:1\u201346.","journal-title":"Adv Immunol"},{"key":"1202_CR43","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","volume":"29","author":"J Trotman","year":"2011","unstructured":"Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, et al. Positron emission tomography\u2013computed tomography (PET\u2013CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET\u2013CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29:3194\u2013200.","journal-title":"J Clin Oncol"},{"key":"1202_CR44","doi-asserted-by":"crossref","unstructured":"Dupuis J, Meignan M, Julian A, Tychyj-Pinel C, Berriolo-Riedinger A, Brice P, et al. Significant prognostic impact of [18F]fluorodeoxyglucose-PET scan performed during and at the end of treatment with R\u2013CHOP in high-tumor mass follicular lymphoma patients: a GELA\u2013GOELAMS Study. ASH annual meeting abstracts;118(21):877.","DOI":"10.1182\/blood.V118.21.877.877"},{"issue":"2","key":"1202_CR45","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.beha.2011.03.002","volume":"24","author":"T Meerten van","year":"2011","unstructured":"van Meerten T, Hagenbeek A. Novel antibodies against follicular non-Hodgkin\u2019s lymphoma. Best Pract Res Clin Haematol. 2011;24(2):231\u201356.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"1202_CR46","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1517\/14712598.2012.668881","volume":"12","author":"TM Illidge","year":"2012","unstructured":"Illidge TM. Obinutuzumab (GA101)\u2014a different anti-CD20 antibody with great expectations. Expert Opin Biol Ther. 2012;12(5):543\u20135.","journal-title":"Expert Opin Biol Ther"},{"issue":"22","key":"1202_CR47","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2012-01-404368","volume":"119","author":"G Salles","year":"2012","unstructured":"Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J, Pisa P, Cartron G. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012;119(22):5126\u201332.","journal-title":"Blood"},{"key":"1202_CR48","doi-asserted-by":"crossref","unstructured":"Samaniego F, Hagemeister F, Mclaughlin P, et al. High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. J Clin Oncol. 2011;29:suppl; abstr 8030.","DOI":"10.1200\/jco.2011.29.15_suppl.8030"},{"issue":"2","key":"1202_CR49","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.beha.2011.03.006","volume":"24","author":"BD Cheson","year":"2011","unstructured":"Cheson BD. New agents in follicular lymphoma. Best Pract Res Clin Haematol. 2011;24(2):305\u201312.","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1202-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-012-1202-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1202-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T07:16:32Z","timestamp":1594797392000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-012-1202-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,30]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["1202"],"URL":"https:\/\/doi.org\/10.1007\/s12185-012-1202-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,30]]}}}